Viz.ai has raised $71 million in a series C round to expand its artificial intelligence platform beyond stroke. Previously, the company raised $50 million in a series B round and has raised $150 million since inception.

The round was led by Scale Venture Partners and Insight Partners with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors, and Susa Ventures. 

Proceeds will bring Viz.ai’s Intelligent Care Coordination A.I. Platform into areas of acute care such as cardiology, pulmonary, and trauma. The financing will also allow the company to expand into new global markets.

"This latest round of funding validates the potential of Viz.ai’s technology, both in and beyond stroke care coordination," Chris Mansi, co-founder and CEO of Viz.ai, said in a release. "The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system both in the United States and Europe."

The firm’s flagship product is Viz LVO. The technology uses advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat.

In a multi-center study using Viz LVO found a median time-to-notification of 5 minutes and 45 seconds across all of the sites involved when using the technology. In the study, containing the largest health AI data set to date, Viz LVO achieved 96% sensitivity and 94% specificity in identifying large vessel occlusions in 2,544 consecutive patients from 139 hospitals using scanners from multiple manufacturers.

The past few years have been fruitful for Viz.ai. MD+DI named Viz.ai as one of six AI Companies Set to Rock Medtech. And not only did the company secure a few nods from FDA – it was also involved in a collaboration with Medtronic.